抗うつ薬市場：薬物クラス、適応症、投与経路、流通チャネル別-2023～2030年の世界予測

抗うつ薬の世界市場は、2023年に207億1,000万米ドル、CAGR 9.60%で大幅な成長が予測され、2030年には399億9,000万米ドルという驚異的な規模に達する見込みです。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の抗うつ薬市場を評価するために不可欠です。ビジネス戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.抗うつ薬の世界市場規模および予測は？

2.予測期間中、世界の抗うつ薬市場を形成するCOVID-19の阻害要因と影響は？

3.抗うつ薬の世界市場において予測期間中に投資すべき製品/セグメント/用途/分野は？

4.抗うつ薬の世界市場における競争戦略は？

5.抗うつ薬の世界市場における技術動向と規制の枠組みは？

6.抗うつ薬の世界市場における主要ベンダーの市場シェアは？

7.抗うつ薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • PTSD、OCD、不安障害の発生率の増加
    • 精神的健康問題に対する政府の好意的な取り組みとキャンペーン
    • 精神保健機関と専門家の数の増加
  • 抑制要因
    • 抗うつ薬に関連する副作用とコスト
  • 機会
    • 斬新な抗うつ薬開発のための革新的なソリューション
    • 新薬に対する新たな規制当局の承認とSSRI薬の使用量の増加
  • 課題
    • メンタルヘルス治療を取り巻く社会的偏見
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 抗うつ薬市場：薬物クラス別

• イントロダクション
• モノアミンオキシダーゼ阻害剤
• 再取り込み阻害剤
• 選択的セロトニン再取り込み阻害剤
• セロトニン拮抗薬
• セロトニン-ノルアドレナリン再取り込み阻害剤
• 三環系抗うつ薬

第7章 抗うつ薬市場：適応症別

• イントロダクション
• 不安障害
• 注意欠陥多動性障害
• 大鬱病性障害

第8章 抗うつ薬市場：投与経路別

• イントロダクション
• 注射
• 経口

第9章 抗うつ薬市場：流通チャネル別

• イントロダクション
• 病院薬局
• オンライン薬局
• 小売薬局

第10章 南北アメリカの抗うつ薬市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の抗うつ薬市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの抗うつ薬市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別
  • 合併・買収
  • 契約、コラボレーション、パートナーシップ
  • 投資、資金調達
  • 受賞・表彰・拡大

第14章 掲載企業一覧

第15章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. ANTIDEPRESSANTS DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. ANTIDEPRESSANTS DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. ANTIDEPRESSANTS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 5. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
• FIGURE 6. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
• FIGURE 7. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
• FIGURE 8. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 9. ANTIDEPRESSANTS DRUGS MARKET DYNAMICS
• FIGURE 10. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 18. ANTIDEPRESSANTS DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 19. ANTIDEPRESSANTS DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. ANTIDEPRESSANTS DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. ANTIDEPRESSANTS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 5. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MONOAMINE OXIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SEROTONIN ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 12. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ANXIETY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 16. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 19. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. ANTIDEPRESSANTS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 58. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 131. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 147. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 149. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 151. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 153. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 190. ANTIDEPRESSANTS DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 191. ANTIDEPRESSANTS DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 192. ANTIDEPRESSANTS DRUGS MARKET LICENSE & PRICING

The Global Antidepressants Drugs Market is forecasted to grow significantly, with a projected USD 20.71 billion in 2023 at a CAGR of 9.60% and expected to reach a staggering USD 39.99 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Antidepressants Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Antidepressants Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Class, market is studied across Monoamine Oxidase Inhibitors, Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Serotonin Antagonist, Serotonin-Norepinephrine Reuptake Inhibitors, and Tricyclic Antidepressants. The Selective Serotonin Reuptake Inhibitors commanded largest market share of 32.67% in 2022, followed by Serotonin-Norepinephrine Reuptake Inhibitors.

Based on Indication, market is studied across Anxiety Disorders, Attention Deficit Hyperactivity Disorder, and Major Depressive Disorder. The Anxiety Disorders commanded largest market share of 32.78% in 2022, followed by Major Depressive Disorder.

Based on Route of Administration, market is studied across Injectable and Oral. The Oral commanded largest market share of 54.57% in 2022, followed by Injectable.

Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Retail Pharmacy commanded largest market share of 59.97% in 2022, followed by Hospital Pharmacy.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 37.56% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Antidepressants Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Antidepressants Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antidepressants Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antidepressants Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Antidepressants Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Antidepressants Drugs Market?

6. What is the market share of the leading vendors in the Global Antidepressants Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Antidepressants Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Antidepressants Drugs Market, by Drug Class, 2022 vs 2030
• 4.3. Antidepressants Drugs Market, by Indication, 2022 vs 2030
• 4.4. Antidepressants Drugs Market, by Route of Administration, 2022 vs 2030
• 4.5. Antidepressants Drugs Market, by Distribution Channel, 2022 vs 2030
• 4.6. Antidepressants Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidences of PTSD, OCD, and anxiety issues
    • 5.1.1.2. Favorable government initiatives and campaigns for mental health problems
    • 5.1.1.3. Rise in number of mental health institutions and professionals
  • 5.1.2. Restraints
    • 5.1.2.1. Associated side effects and cost of antidepressants drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Innovative solutions for the development of novel antidepressants drugs
    • 5.1.3.2. Emerging regulatory approvals for new drugs and rising usage of SSRIs drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Social stigma surrounding mental health treatments
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Antidepressants Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Monoamine Oxidase Inhibitors
• 6.3. Reuptake Inhibitors
• 6.4. Selective Serotonin Reuptake Inhibitors
• 6.5. Serotonin Antagonist
• 6.6. Serotonin-Norepinephrine Reuptake Inhibitors
• 6.7. Tricyclic Antidepressants

7. Antidepressants Drugs Market, by Indication

• 7.1. Introduction
• 7.2. Anxiety Disorders
• 7.3. Attention Deficit Hyperactivity Disorder
• 7.4. Major Depressive Disorder

8. Antidepressants Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Injectable
• 8.3. Oral

9. Antidepressants Drugs Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacy
• 9.3. Online Pharmacy
• 9.4. Retail Pharmacy

10. Americas Antidepressants Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Antidepressants Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Antidepressants Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. FPNV Positioning Matrix
• 13.2. Market Share Analysis, By Key Player
• 13.3. Competitive Scenario Analysis, By Key Player
  • 13.3.1. Merger & Acquisition
    • 13.3.1.1. Acquisition of CinCor Pharma complete
    • 13.3.1.2. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
  • 13.3.2. Agreement, Collaboration, & Partnership
    • 13.3.2.1. Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck
  • 13.3.3. Investment & Funding
    • 13.3.3.1. RA Capital backs another startup hunting for a better antidepressant
    • 13.3.3.2. Autobahn raises funds for ABX-002 advancement to treat depression
    • 13.3.3.3. Genetika+ Wins Prestigious European Funding to Bring Depression Drug Matching Platform to Market
    • 13.3.3.4. Osmind scores $40M investment to aid in mental health research and treatment
  • 13.3.4. Award, Recognition, & Expansion
    • 13.3.4.1. Alembic Pharma gets USFDA nod to market generic antidepressant drug
    • 13.3.4.2. Zydus gets USFDA nod to market generic medicine for treating depression
    • 13.3.4.3. Axsome Therapeutics Announces FDA Approval of AUVELITY, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
    • 13.3.4.4. Granules India gets USFDA approval for generic antidepressant drug

14. List of Company Mentioned

15. Appendix

• 15.1. Discussion Guide
• 15.2. License & Pricing